Massachusetts Financial Services Co. MA Has $613.12 Million Stock Holdings in Icon Plc $ICLR

Massachusetts Financial Services Co. MA trimmed its stake in Icon Plc (NASDAQ:ICLR) by 6.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,503,553 shares of the medical research company’s stock after selling 248,455 shares during the quarter. Massachusetts Financial Services Co. MA owned 4.34% of Icon worth $613,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sierra Legacy Group raised its holdings in Icon by 2.5% during the third quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock valued at $794,000 after buying an additional 110 shares in the last quarter. Resonant Capital Advisors LLC acquired a new position in shares of Icon during the third quarter valued at about $230,000. First National Advisers LLC lifted its position in shares of Icon by 9.5% in the 3rd quarter. First National Advisers LLC now owns 7,600 shares of the medical research company’s stock worth $1,330,000 after acquiring an additional 662 shares during the period. Stephens Investment Management Group LLC increased its holdings in Icon by 15.7% in the 3rd quarter. Stephens Investment Management Group LLC now owns 480,104 shares of the medical research company’s stock valued at $84,018,000 after buying an additional 65,264 shares during the period. Finally, Wilmington Savings Fund Society FSB lifted its stake in Icon by 153.4% during the third quarter. Wilmington Savings Fund Society FSB now owns 332 shares of the medical research company’s stock worth $58,000 after purchasing an additional 201 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ICLR has been the topic of several analyst reports. Truist Financial reaffirmed a “hold” rating and issued a $222.00 target price (down previously from $231.00) on shares of Icon in a report on Thursday, January 8th. Robert W. Baird set a $217.00 target price on Icon in a report on Friday, January 9th. UBS Group set a $220.00 price target on Icon in a report on Friday, October 24th. Zacks Research raised Icon from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 25th. Finally, Bank of America lowered Icon from a “buy” rating to a “neutral” rating and set a $195.00 target price for the company. in a research note on Monday, December 15th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, Icon currently has a consensus rating of “Moderate Buy” and a consensus price target of $199.87.

Icon Price Performance

Shares of ICLR stock opened at $182.61 on Monday. The firm has a market cap of $14.75 billion, a price-to-earnings ratio of 24.71, a PEG ratio of 3.84 and a beta of 1.26. Icon Plc has a 12 month low of $125.10 and a 12 month high of $211.00. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average price of $179.24 and a 200 day moving average price of $174.35.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.